This document provides a summary of the September 19, 2011 report from the Communications, Outreach and Engagement Committee (COEC) of the Patient-Centered Outcomes Research Institute (PCORI). The summary includes updates on recent public input opportunities, promoting PCORI funding opportunities, redesigning the PCORI website, outreach plans, and growing the PCORI communications staff.
Presented by
Lawrence Becker,
PCORI (Patient-Centered Outcomes Research Institute) Board of Governers, and Director, Strategic Partnerships and Alliances, Xerox Corporation
Learn about considerations when budgeting for patient and public engagement, and use of CHI's PE budgeting tool when applying for funding.
About this session
CHI's Lunchtime Learning is open to all researchers, decision-makers, clinicians, patients and members of the public who want to learn more about the theory and practice of meaningful, inclusive, and safe patient and public engagement.
Following this session, attendees should be able to:
• Identify key considerations when budgeting for patient engagement;
• Access and use CHI's Patient Engagement Budgeting Tool; and
• Develop a draft budget that can be attached to funding applications.
Presented by
Lawrence Becker,
PCORI (Patient-Centered Outcomes Research Institute) Board of Governers, and Director, Strategic Partnerships and Alliances, Xerox Corporation
Learn about considerations when budgeting for patient and public engagement, and use of CHI's PE budgeting tool when applying for funding.
About this session
CHI's Lunchtime Learning is open to all researchers, decision-makers, clinicians, patients and members of the public who want to learn more about the theory and practice of meaningful, inclusive, and safe patient and public engagement.
Following this session, attendees should be able to:
• Identify key considerations when budgeting for patient engagement;
• Access and use CHI's Patient Engagement Budgeting Tool; and
• Develop a draft budget that can be attached to funding applications.
The following resource was developed by RESYST for a research uptake workshop held in Kilifi, Kenya.
In this resource:
- Understand the importance of strategic planning for research uptake
- Familiarise key aspects of a research uptake strategy
- Develop research uptake objectives for your research group, project, hub or an event
- Identify key stakeholders using stakeholder analysis techniques
- Review communications channels, outputs and activities
- Explore indicators and tools for monitoring and evaluation
- Key questions to consider in a research uptake strategy
Find more: http://resyst.lshtm.ac.uk/resources/resource-bank-research-uptake
Reflections on Research and Evaluation Reality Jan 2016John Wren
This PPT presents personal reflections on the challenging environment many researchers and evaluators in government agencies face. The reflections come from 15 years of experience, and observing and listening and talking to colleagues in NZ and Australia.
Grant Proposals (SF 424): K08-K23 Applications and Individual CDAsUCLA CTSI
UCLA CTSI K Workshop - February 4, 2016
Isidro B. Salusky, MD
Distinguished Professor of Pediatrics at UCLA Chief, Division of Pediatric Nephrology
Director, Clinical Translational Research Center
Associate Dean of Clinical Research
K99/R00 Awards - Pathways to IndependenceUCLA CTSI
UCLA CTSI K Workshop - February 4, 2016* (*updated Feb 1, 2017)
Christopher Evans, PhD
Professor of Psychiatry and Biobehavioral Sciences at UCLA
Director, Brain Research Institute
UCLA CTSI K Workshop - February 4, 2016
Mariko Ishimori, MD
Associate Health Sciences Clinical Professor of Medicine
Cedars-Sinai Medical Center CTSI Associate Leader UCLA Clinical & Translational Science Institute
Navigating the NIH K Award Process (July 2015)UCLA CTSI
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Program Leader, Research Education, Training and Career Development Program (CTSI-ED)
UCLA CTSI K Workshop
Learn to navigate through the possible career development awards (CDAs) available to you and which you should target.
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, UCLA CTSI Workforce Development
Presentation date: February 09, 2017
How to Anticipate and Plan for an R Grant Application (2020)UCLA CTSI
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Chief, Division of General Internal Medicine and Health Services Research
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, UCLA CTSI Workforce Development
UCLA CTSI K Workshop - February 4, 2016
Learn to navigate through the possible career development awards (CDAs) available to you and which you should target.
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, Research Education, Training and Career Development Program
The NIHR Research Design Service provides support to NHS staff and academics preparing research proposals for submission to peer-reviewed funding competitions for applied health or social care research.
Bringing the patient voice into GSK for educational, awareness and patient ce...Nowgen
"Bringing the patient voice into GlaxoSmithKline for educational, awareness and patient centred decisions within medicine development", presented by Kay Warner, Global Manager, Focus on the Patient, GlaxoSmithKline, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
A Tactical Approach to Writing Your Grant Application (2020)UCLA CTSI
William Parks, PhD
Professor of Medicine at Cedars-Sinai Medical Center and UCLA
Associate Dean for Graduate Research Education
Scientific Director, Women’s Guild Lung Institute
Estrategias para Implementación de las Guías de Práctica ClínicaGuíaSalud
"Estrategias para Implementación de las Guías de Práctica Clínica" presentación realizada por Andrew D. Oxman, investigador del Norwegian Institute of Public Health en las Jornadas Científicas de GuíaSalud (Madrid, 4 abril 2016)
Considerations in Applying for a K99 Award: the NIH "Pathway to Independence"...UCLA CTSI
Considerations in Applying for a K99 Award: the NIH "Pathway to Independence"
Presented by:
Christopher Evans, PhD
Professor of Psychiatry and Biobehavioral Sciences at UCLA
Director, Brain Research Institute
Presentation date: February 09, 2017
Let's Talk Research Annual Conference - 24th-25th September 2014 (Dr Mal Palin)NHSNWRD
"NIHR Administered Personal Research Training Award": Dr Mal Palin's presentation reviewed opportunites given by the NIHR Trainees Coordinating Centre and presented the experiences of an existing award holder.
The following resource was developed by RESYST for a research uptake workshop held in Kilifi, Kenya.
In this resource:
- Understand the importance of strategic planning for research uptake
- Familiarise key aspects of a research uptake strategy
- Develop research uptake objectives for your research group, project, hub or an event
- Identify key stakeholders using stakeholder analysis techniques
- Review communications channels, outputs and activities
- Explore indicators and tools for monitoring and evaluation
- Key questions to consider in a research uptake strategy
Find more: http://resyst.lshtm.ac.uk/resources/resource-bank-research-uptake
Reflections on Research and Evaluation Reality Jan 2016John Wren
This PPT presents personal reflections on the challenging environment many researchers and evaluators in government agencies face. The reflections come from 15 years of experience, and observing and listening and talking to colleagues in NZ and Australia.
Grant Proposals (SF 424): K08-K23 Applications and Individual CDAsUCLA CTSI
UCLA CTSI K Workshop - February 4, 2016
Isidro B. Salusky, MD
Distinguished Professor of Pediatrics at UCLA Chief, Division of Pediatric Nephrology
Director, Clinical Translational Research Center
Associate Dean of Clinical Research
K99/R00 Awards - Pathways to IndependenceUCLA CTSI
UCLA CTSI K Workshop - February 4, 2016* (*updated Feb 1, 2017)
Christopher Evans, PhD
Professor of Psychiatry and Biobehavioral Sciences at UCLA
Director, Brain Research Institute
UCLA CTSI K Workshop - February 4, 2016
Mariko Ishimori, MD
Associate Health Sciences Clinical Professor of Medicine
Cedars-Sinai Medical Center CTSI Associate Leader UCLA Clinical & Translational Science Institute
Navigating the NIH K Award Process (July 2015)UCLA CTSI
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Program Leader, Research Education, Training and Career Development Program (CTSI-ED)
UCLA CTSI K Workshop
Learn to navigate through the possible career development awards (CDAs) available to you and which you should target.
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, UCLA CTSI Workforce Development
Presentation date: February 09, 2017
How to Anticipate and Plan for an R Grant Application (2020)UCLA CTSI
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Chief, Division of General Internal Medicine and Health Services Research
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, UCLA CTSI Workforce Development
UCLA CTSI K Workshop - February 4, 2016
Learn to navigate through the possible career development awards (CDAs) available to you and which you should target.
Carol M. Mangione, MD, MSPH
Barbara A. Levey MD & Gerald S. Levey MD Endowed Chair
Professor of Medicine and Public Health at UCLA
Associate Director, UCLA Clinical and Translational Science Institute
Leader, Research Education, Training and Career Development Program
The NIHR Research Design Service provides support to NHS staff and academics preparing research proposals for submission to peer-reviewed funding competitions for applied health or social care research.
Bringing the patient voice into GSK for educational, awareness and patient ce...Nowgen
"Bringing the patient voice into GlaxoSmithKline for educational, awareness and patient centred decisions within medicine development", presented by Kay Warner, Global Manager, Focus on the Patient, GlaxoSmithKline, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
A Tactical Approach to Writing Your Grant Application (2020)UCLA CTSI
William Parks, PhD
Professor of Medicine at Cedars-Sinai Medical Center and UCLA
Associate Dean for Graduate Research Education
Scientific Director, Women’s Guild Lung Institute
Estrategias para Implementación de las Guías de Práctica ClínicaGuíaSalud
"Estrategias para Implementación de las Guías de Práctica Clínica" presentación realizada por Andrew D. Oxman, investigador del Norwegian Institute of Public Health en las Jornadas Científicas de GuíaSalud (Madrid, 4 abril 2016)
Considerations in Applying for a K99 Award: the NIH "Pathway to Independence"...UCLA CTSI
Considerations in Applying for a K99 Award: the NIH "Pathway to Independence"
Presented by:
Christopher Evans, PhD
Professor of Psychiatry and Biobehavioral Sciences at UCLA
Director, Brain Research Institute
Presentation date: February 09, 2017
Let's Talk Research Annual Conference - 24th-25th September 2014 (Dr Mal Palin)NHSNWRD
"NIHR Administered Personal Research Training Award": Dr Mal Palin's presentation reviewed opportunites given by the NIHR Trainees Coordinating Centre and presented the experiences of an existing award holder.
Understanding impact through alternative metrics: developing library-based as...Kristi Holmes
There’s never been a more critical need to better understand the impact of research efforts. The challenging state of funding models (1) and an enhanced pressure on young investigators to stand out from the crowd magnify this need as well as the perceived value of locally based impact services. These services are leveraged by a diverse range of stakeholders, from individuals to university-level decision makers and strategists. Individuals often wish to better demonstrate impact of published works to promotion committees or describe the impact of research studies to funding agencies when applying for funding or complying with institution-level or federal reporting exercises. Research groups, departments, and institutions often wish to discover how research findings are being used to promote science and gain a better overall view of research publications and outputs.
Libraries are particularly well poised to meet the need to understand a more nuanced view of impact. Libraries are trusted, neutral parties with a tradition of service and support and often act as technology hubs on campus with IT and data expertise. Librarians are trained information professionals with information and searching skills and a keen understanding of the research, education, clinical landscape of their institution. This presentation will discuss general trends in the field, including an overview of resources, assessment frameworks and tools; strategies for partnering with stakeholders; and examples of library based service models, from basic services to highly integrated library-based core research units.
(1) http://dx.doi.org/10.1126/scitranslmed.aac5200
Evidence to Care: Mobilizing Childhood Disability Research into Practice
Dr. Shauna Kingsnorth
Evidence to Care Lead
Clinical Study Investigator
Assistant Professor (status), Department of Occupational Science
and Occupational Therapy, University of Toronto
Holland Bloorview Kids Rehabilitation Hospital
skingsnorth@hollandbloorview.ca
Presented at: Canadian Knowledge Mobilization Forum
Saskatoon, Saskatchewan June 9, 2014
Patient Engagement for Data Science, Technology & EngineeringCHICommunications
Learn the necessities and relationship between patient engagement and data science, engineering and technology.
Presented by Trish Roche, CHI's Knowledge Translation Practice Lead, this presentation is geared towards professionals in data science looking to hone their skills in patient engagement.
How do we find our way through the forest of requirements, options, exemptions, variations and special cases that institutions and individuals have to handle with Open Access policies? The Open Access policy environment is growing more complex and more demanding in its needs, and now more significant in its implications.
Similar to Board of Governors Meeting, South Sea Tea Washington (20)
Slide presentation for the June 4, 2014 joint PCORI/ National Institute on Aging (NIA) of the National Institutes of Health webinar. This webinar announced the selection of the research team that will carry out a major, five-year, $30 million patient-centered study of the effectiveness of individually tailored care plans to help older individuals avoid falls and related injuries.
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
The slide presentation from PCORI'S Advisory Panel on Assessment of Prevention, Diagnosis, and Treatment Options April 28-29, 2014 meeting in Alexandria, VA.
The slide presentation from the combined meeting of PCORI'S Advisory Panels on Patient Engagement and Addressing Disparities April 28, 2014 meeting in Alexandria, VA.
Slide presentation from Day Two of the PCORnet Partners meeting. The January 21-2, 2014 meeting took place at the Brookings Institute. This event launched the development of the nation’s most ambitious and promising clinical research network aimed at delivering high quality care through patient-centered outcomes research.
Slide presentation from Day One of the PCORnet Partners meeting. The January 21-2, 2014 meeting took place at the Brookings Institute. This event launched the development of the nation’s most ambitious and promising clinical research network aimed at delivering high quality care through patient-centered outcomes research.
Slide presentation from the October 30, 2013 webinar which described the process and rationale for PCORI’s unique approach to reviewing research proposals for funding.
Slide presentation from the November 13, 2013 webinar. This webinar was an opportunity to learn more about the Tier 1 Pipeline Awards, what type of projects PCORI is looking to fund, and how to apply.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Board of Governors Meeting, South Sea Tea Washington
1. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
September 19, 2011
Patient-Centered Outcomes Research Institute
Communications, Outreach and
Engagement Committee (COEC)
Report
2. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
COEC Members
2
• Sharon Levine, MD (Chair)
• Debra Barksdale, PhD, RN
• Robert Jesse, MD, PhD
• Grayson Norquist, MD, MSPH
• Ellen Sigal, PhD
• Harlan Weisman, MD
3. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
COEC Charter
3
The Communication, Outreach and Engagement Committee shall advise and
assist the Board of Governors of PCORI, and provide recommendations to the
Board, regarding:
1. The Institute’s communications and branding work,
2. Strategies to engage all stakeholders in the work of PCORI, and
3. Methodologically sound approaches to disseminating and implementing the
research results and ensuring their utility to patients
and clinicians
4. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
COEC Report to the Board
4
I. Recent Opportunities for Public Input (Update)
II. Promoting PCORI RFPs (Update)
III. Redesigned PCORI Website (Update)
IV. Outreach Plan for Pilot Project Funding Announcement
(Recommendation for Decision)
V. Stakeholder Outreach (Update)
VI. Speakers Bureau (Update)
VII.PCORI Communications Staff (Update)
5. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Recent Opportunities for Public Input
5
• Working definition of “patient-centered outcomes research”
– Nearly 600 responses were received (July 20-September 2,
2011)
– All responses received through the website or emailed PDFs will
be posted on pcori.org
– PCORI issued an RFP to solicit proposals for the analysis and
summarization of the input received and for recommendations
on methodologies to receive further input from patient
audiences
6. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Analysis and Summary of Input on Working
Definition of PCOR
6
Issue RFP (and reach out to potential applicants) August 24, 2011
Deadline for applications September 9, 2011
Complete review of applications September 16, 2011
Complete contract with chosen contractor September 19, 2011
Submit Phase I findings and draft questions for focus
groups
September 30, 2011
PCORI completes revision of PCOR Definition October 26, 2011
Revise questions for focus groups November 9, 2011
Focus Groups (or other way of seeking patient input) November 18, 2011
Report due to PCORI December 16, 2011 (with
preliminary report in time for
December 8 meeting)
PCORI completes further revisions of PCOR Definition January 15, 2012
PCORI Board considers revised PCOR Definition January 18, 2012
7. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Working Definition of PCOR:
A Foundation for PCORI’s Work
7
• At the time of PCORI’s creation, “patient-centered outcomes
research” (PCOR) was not a commonly used term, nor had it been
formally defined
• Defining PCOR helps clarify PCORI’s focus and scope of work
• Through iterative and transparent processes that elicit feedback
from all stakeholders, including patients, we will continue to revise
the definition, ensuring it:
– Emphasizes the “patient-centered” focus of PCORI’s mission
– Is consistent with the intent of the statute that established PCORI
– Is broad enough to support the range of research PCORI should fund
8. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Recent Opportunities for Public Input
8
• Initial topics for PCORI pilot
projects.
– More than 150 responses
were received
(August 1-30, 2011)
– Responses provided to the
PDC Working Group to
review and update topics
as appropriate.
• 89.26% Self Identified
• 10.74% Anonymous
• 59.76% Responded as Individual
• 40.27% On behalf of an Organization
Respondents
• 40.94% Academia
• 23.49% Provider
• 17.45% Patient
• 3.36% Industry
• 0.67% Government
• 11.41% Non-Identified
Organizational Respondents
9. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Promoting PCORI RFPs
9
• To date PCORI has issued 4 Requests for Proposals (RFP)
– Analysis of Input Received on Working Definition of “Patient-Centered Outcomes Research”
– Review and Synthesis of Evidence for Eliciting the Patient's Perspective in Patient-Centered
Outcomes Research (Literature Review)
– Expert Stakeholder Interviews to Identify Evidence for Eliciting the Patient's Perspective in
Patient-Centered Outcomes Research (Interviews)
– Methods for Setting Priorities in Research (White Papers)
• For each RFP, PCORI performed outreach to: email list subscribers (620+),
supplemental lists of clinical and translational research centers (60+), academic
research institutions (30+), and provider and advocacy organizations (30+)
• PCORI is an independent, non-profit, non-governmental organization. All PCORI
funding announcements will be posted on pcori.org. PCORI funding announcements
will not be published in the Federal Register
11. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Redesigned PCORI Website
11
• Includes visual changes based on logo and color palette approved
at July Board Meeting
• Designed to be more user friendly
• Will support the expansion of PCORI content and opportunities for
interaction as work progresses
• Expanded features include:
– Easier mechanisms for joining PCORI mailing list and providing
general input
– An “Executive Director’s Corner” that provides regular updates
on PCORI’s latest developments
12. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Outreach Plan for Pilot Project Funding
Announcement
12
• Post announcement on pcori.org
• Direct email to stakeholders and potential applicants
• Conduct proactive media relations
• Promote the opportunity though grassroots outreach
• Integrate the announcement with speakers bureau presentations
• Host a Q&A teleconference for applicants
13. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Stakeholder Outreach
13
PCORI’s engagement with stakeholders around Board meetings
• Stakeholder discussion forum
March
St. Louis, MO
• Stakeholder discussion forum
May
New York, NY
• Two small group meetings with patients and caregivers
• Eight small group meetings with 43 stakeholder organizations
July
Washington, DC
• Invited presentations from Northwest Pacific stakeholders
September
Seattle, WA
• Site visits to clinical care facilities
November
New Orleans, LA
14. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Seattle Stakeholder Engagement Forum
14
• PCORI has invited individuals and organizations from the Pacific
Northwest to make brief presentations to the Board about their
work or perspective and how it can inform PCORI’s work
• Native American/Alaska Native perspectives
• Complementary and alternative medicine researchers and
providers
• Outcomes and comparative effectiveness researchers
• Monday, September 19, 7:00-9:00 p.m. PT
• Open to the public
15. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Speakers Bureau
15
PCORI has presented at 24 meetings since March
Recent Speaking Engagements
• 7/25 – IOM CER Innovation Collaborative Meeting
• 7/25 – Center for Medical Technology Policy CER Institute
• 8/12 – Consumers United for Evidence Based Health Care Annual Meeting
• 8/25 – Florida Chiropractic Association National Convention & Expo
• 9/9 – University of Michigan School of Nursing
• 9/16 – Oregon Institute for Patient-Centered Comparative Effectiveness Annual Research Intensive
Upcoming Opportunities
• 9/27 -- AdvaMed 2011 MedTech Conference
• 9/28 – Partnership to Improve Patient Care Annual Membership Forum
• 10/11 – NIH National Center for Research Resources Clinical and Translational Science Awards Program
• 10/12 – Comparative Effectiveness Research Summit
• 10/12 – American Academy of Nursing, Council of Advancement of Nursing Science 2011 Special Topics
Conference
• 10/19 – Health Industry Forum
• 10/20 – Pfizer Health Advocates Leadership Breakfast
16. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
PCORI Communications Staff
16
• Seeking applicants for three positions:
– Director of Communications
– Director of Patient Engagement
– Director of Stakeholder Engagement
• Staff will develop and implement strategic communications plan
• Distinct engagement officers for patients and other stakeholders,
recognizing their need for different engagement mechanisms
17. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
September 19-20, 2011
Seattle, WA
Executive Director Update
Board of Governors
PATIENT-CENTERED OUTCOMES
RESEARCH INSTITUTE
18. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Objectives for today
Highlight PCORI Activities since July 2011 BoG Meeting
Discuss Growing the PCORI Staff
Consider Critical Timelines/Milestones for Next 9 Months
19. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
PCORI Activities – (Staff, Board, MC together)
Establishing Policies and Practice
HR Policies
Purchasing/RFP policies
COI policies
Research Policies
Re-designing Website
Outreach
Developing IT Infrastructure
Growing Staff
Finding Long-term Space
20. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
4
• $48 per sq. foot
• Attractive, not
• extravagant
• 13,000 sq feet
• Close to Metro
• Green building
• Move-in: February
PCORI’s Long-Term Home
1828 L Street, DC
21. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Urgent Issues Coming Out of July BoG Meeting:
Address the need for greater clarity in decision-making and take
steps to find more time for substantive discussions among board,
with MC
Patient Engagement! - Officer, Advisory Panel
Get started on the National Priorities and Research Agenda!
Support the PDC in preparing PCORI Pilot Projects RFP and review
Support the MC in getting the RFPs out for the Methodology Report
22. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Patient Engagement
6
Patient-Engagement Working Group formed;
Job Description for Director of Patient Engagement drafted
Directors of Stakeholder Engagement and Director of Communications Added
All three positions are posted and a search is underway
Patient
Engagement
Communi-
cations
Stakeholder
Engagement
External
Engagement
23. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Program Development Committee
National Priorities and Research Agenda
• C Clancy and A Epstein, co-chairs
• Environmental scan on past CER analysis and developed an initial
framework for the National Priorities which will serve as the
foundation for developing specific priorities
• Recognized the close link between the National Priorities and
Research Agenda (H Krumholz and L Hole-Curry, co-chairs)
• Developed a timeline and notional process for engaging
stakeholders as part of the National Priorities development timeline
24. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Developing PCORI’s National Priorities
and Research Agenda
8
Collect
Stakeholder
Input
Develop Candidate Priorities
Public
Comment
Finalize
Priorities
Develop
Candidate
Priorities
Underway Sept - Nov Dec-Feb March
Collect
Stakeholder
Input
Public
Comment
Finalize
Research
Agenda
April
Feb - Mar
Sept - Jan
PRIORITIES:
RESEARCH AGENDA:
25. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Program Development Committee
PCORI Pilot Projects
C Goertz and G Hunt co-chairing this process.
Public Input has been reviewed and incorporated into revised “areas
of interest” in the PCORI Funding Announcement (PFA)
An application form and instructions have been developed and
revised
Working closely with NIH staff on defining each step in the
application and review process
26. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Supporting Methodology Committee
Interim researcher process established; at least one
already working
RFPs (2) for Patient-centeredness Working Group posted
RFP (1) for Research Prioritization Working Group posted
Review Process in Development, including COI policies for
review
27. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Definition of PCOR
Input on the working definition of “patient-centered outcomes research”
gathered (n=600); to be posted shortly after anonymization
RFP posted for qualitative analysis and summarization of the input
received and for recommendations on methodologies to receive further
input from patient audiences posted on PCORI website
12 responses received and reviewed
First PCORI research contract issued on 9/16 to National Opinion
Research Center
II
MC
I
9/16 9/30 11/15 12/31
Synthesis
& Question
Generation
Revision of
Definition
Testing of
Revised
Definition
Preparation of
MS for Publication
Led by MC
28. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Three Engagement
Directors
Applications
Arrive
LOI’s
Arrive
Growing PCORI Staff:
09/18/11 –
09/20/11
We are here
11/1/11 2/1/12 05/1/12
04/1/12
1/1/12
COO
Begins
Mark
In!
Director
Finance
Begins
First
Scientists
Additional
Scientists
Additional
Admin
Ass’ts
Director of
Staff
12/1/11 3/1/12
Funding
Decision
Made
Funding
Issued
Program
Staff Hiring
Begins
Finance/Grant
Staff
29. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Growing PCORI Staff
13
Research Scientist
Patient engagement
Research
Research Scientist
Stakeholder Engagement
Research Scientist
Communicaiton/Disseminat
ion Research
Research Scientist(s)
Comparative Clinical
Effectiveness Research
Director
Patient Engagement
Director*
Stakeholder Eng.
Director
Communications
Chief Financial Officer
(CFO)
Director
HR
Director
Director
Grants Management
Research Scientist(s)
Evidence Synthesis
External
Engagement
Executive Director
Chief Operating Officer
Chief Science Officer
30. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Critical Issues: September 2011 – June 2012
14
Gathering Stakeholder Input on National Priorities and Research Agenda
Thorough, balanced, incorporated
September – November:
November- December:
Finalizing First Draft of Priorities (Prior to Public Comment)
How are Priorities expressed, what’s in, is anything out?
January – February:
Finalizing First Draft of Research Agenda (Prior to Public Comment)
What (specifically) is in, out – what will the first RFAs fund?
Data Infrastructure Grants?
Translation/Implementation Research?
Systems research?
Pharmacogenetics?
Large clinical trials?
31. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Finance & Administration Committee
September 20, 2011, Seattle, WA
PATIENT-CENTERED OUTCOMES
RESEARCH INSTITUTE
32. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Bylaws Revisions
• GAO currently reviewing
• Committee Name Change: Finance, Administration & Audit
• Adoption Proposed at November BOG Meeting
33. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Audit Update
• Released this week
• Bidders selected by annual revenues
• Proposals by end of October
• Recommendation to BOG
• Field work in November/December
• Completed audit by March
• Provided to GAO for report to Congress due April 1st
34. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Financial Statements – August 31, 2011
• Statement of Financial Position: Total Assets of $46.3M; $5M Cash
on Hand
• Expenditures:
– Budget: $7.5M
– Actual: $3.7M
– Positive variances in Board compensation, management fees,
professional services, travel
– Negative variance in conferences
35. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
Conflicts of Interest Policy
• Working group created
Members: Larry Becker, Chair
Debra Barksdale
Arnie Epstein
Sherine Gabriel
Bob Jesse
• Group is gathering key documents
36. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
1
September 19, 2011
PCORI Methodology Committee
Progress Report
Sherine E. Gabriel, MD, MSc
Sharon-Lise T. Normand, PhD
PCORI Methodology Committee
37. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
2
• Establishment
• Overview
• Timeline
• Structure
• Mission
• Scope of Work
• Progress to Date
• Next Steps
• Questions
1. Methodology Committee
2. Methodology
Committee Workgroups
3. Wrap Up
• Next Steps
Agenda
38. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
3
Methodology Committee Charge
Establishes priorities to
address gaps in
research methods and
their application
The Methodology
Committee shall make
recommendations
regarding methods for
patient-centered
outcomes research
Provides guidance
about the appropriate
use of methods
39. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
4
Methodology Committee Structure
Methodology Committee
Co Chairs: Sherine Gabriel, MD, Mayo Clinic & Sharon-Lise Normand, PHD, Harvard Medical School
Patient-Centeredness
Research Prioritization
Methods to incorporate the patient
perspective into all phases of PCOR
Methods to inform prioritization of new
research studies
Methods for using data, design, and
statistical analyses to conduct PCOR
Research Methods
Report
Assimilation
40. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
5
Methodology Committee Activity Timeline
Research
Methods
Aug „11 Oct „11 Nov „11 Dec „11
Patient-
Centeredness
Jan „12 Feb „12 Mar „12 Apr „12 May „12
Workshop
Final
Report
Workshop
Identify
Gaps/
Issues
Translation
Table/Tool
Workshop Final
Papers
Due
Final
Draft
Final
Report
Final
Report
Compile
First
Draft
Legend
Research
Prioritization
Report
Assimilation
Feb – Jul „11
Revise Report Outline & Edit Chapters
Final
Report
Final
Papers
Due
Electronic Data Systems Landscape Review
Identify & Implement Voting
Standards Process
Solicitations: White Papers/Identify Experts
Solicitations: Literature Review & Interviews
MC
Charter
MC
Work
Plan
Interim
Researchers
Staffed
PCOR
Definition
Solicitation
Commission White Papers
Sep „11
41. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
6
Methodology Committee Discussion Points
• Importance of methods generated by Patient Centeredness Work
Group for incorporating patient engagement
• Importance of methods generated by Research Prioritization
Work Group vis-à-vis prioritization framework set by the board
• Generation of tools/standards for Methods Report is a multiyear
process
• Importance of continuing to interact with Board to ensure
coordination of efforts
• Board/Methodology Committee teleconference calls were a
productive forum to receive input from the Board regarding their
needs and priorities
42. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
7
• Establishment
• Overview
• Structure
• Timeline
• Mission
• Scope of Work
• Progress to Date
• Next Steps
• Questions
1. Methodology Committee
2. Methodology
Committee Workgroups
3. Wrap Up
• Next Steps
43. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
8
Patient-Centeredness Workgroup
Ethan Basch, MD
Memorial Sloan-Kettering
Cancer Center
Workgroup Chair
Mary Tinetti, MD
Yale University School of
Medicine
Workgroup Co-Chair
Naomi Aronson, PhD
Blue Cross and Blue Shield
Workgroup Member
Brian Mittmann, MD
VA Center for Implementation
Practice & Research Support
Workgroup Member
David Flum, MD, MPH
University of Washington
Report Assimilation Group Liaison
44. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
9
-
Patient Centeredness Mission/Scope of Work
Development and
prioritization of research
questions
Identify methodological standards for incorporating
the patient perspective into three key areas:
Design of study
components, including
selection of interventions,
comparators, and outcomes
(including patient-reported
outcomes)
Processes of clinical
decision-making/care
delivery
45. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
10
Patient Centeredness Progress to Date
Released RFP
for Literature
Review
Released RFP
for Interviews
“Review and Synthesis of
Evidence for Eliciting the
Patient‟s Perspective in
Patient-Centered
Outcomes Research”
“Expert Stakeholder
Interviews to Identify
Evidence for Eliciting the
Patient‟s Perspective in
Patient-Centered Outcomes
Research”
46. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
11
Proposals Due
Awardee Announced
Final Report Due
Oct 6, 2011
Oct 13, 2011
March 1, 2012
Issue Open RFI Plan Workshop
Develop Sections
for Methodology
Report
Patient Centeredness Next Steps
47. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
12
Patient Centeredness Question
How does this work
complement ongoing and
planned activities of the
Board?
48. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
13
Research Prioritization Workgroup
David Meltzer, MD, PHD
University of Chicago
Department of Medicine
Workgroup Chair
John Ioannidis, MD, DSc
Stanford Prevention
Research Center
Workgroup Member
Jean Slutsky, PA, MSPH
Agency for Healthcare
Research and Quality
Workgroup Member
Clyde Yancy, MD
Northwestern University
Feinberg School of Medicine
Workgroup Member
Alfred Berg, MD, MPH
University of Washington
Department of Family Medicine
Report Assimilation Group Liaison
49. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
14
Research Prioritization Mission
Mission
To provide guidance concerning the use of methods to inform the
establishment of research prioritization approaches that best
fulfill PCORI’s mission.
• To the PCORI Board to aid in development and future
refinement of Research Priorities]
• To the broader multi-stakeholder communities to enhance
understanding of PCORI’s approach to research prioritization
and to encourage their engagement in PCORI’s research
prioritization process
50. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
15
-
Commission White
Papers
To prepare a section for the May 2012 Methodology Committee Report
that addresses methods to inform the establishment of research
prioritization
Synthesize White Papers
during January 2012
Workshop
Research Prioritization Scope of Work
Topic
Generation
Gap Analysis in
Systematic
Reviews
Value of
Information
Analysis
Peer Review
Suggest strategies to
identify possible future
priority areas
Suggest standards for how
PCORI systematic reviews
should be performed and
used to generate research
topics
Provide PCORI Board and/or
grant applicants with tools
to quantify expected
benefits of research to
inform priorities
Provide data to inform how
PCORI might design,
evaluate and continually
improve its peer review
process
51. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
16
Research Prioritization Progress to Date
Identified
Methodological
Areas of Interest
in Research
Prioritization
Identified
Interim
Researcher to
Assist
Workgroup
Released RFA
for White
Papers on
September 9,
2011
52. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
17
White Paper Proposals Due
Review and select among White Paper
proposals
Awardee Announced
Sept 30, 2011
Oct 1- 13, 2011
Oct. 14 2011
Explore the role of research prioritization methods vis-à-vis the broader
PCORI research prioritization process
Engage researchers as needed to fill in expected gaps from White Papers
Research Prioritization Next Steps
53. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
18
Research Prioritization Question
How can we best work with you to
understand your evolving plans for
research prioritization so the
methods we are studying can be of
most use to you?
54. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
19
Research Methods Workgroup
Steven Goodman, MD, MHS, PHD
The John Hopkins University
School of Medicine and Public Health
Workgroup Chair
Mike Lauer, MD
National Institute of Health
National Heart, Lung, and
Blood Institute
Workgroup Member
Robin Newhouse, PHD RN
University of Maryland
School of Nursing
Workgroup Member
Sebastian Schneeweiss,
MD, ScD
Harvard Medical School
Workgroup Member
Mark Helfand, MD MPH MS
Oregon Health & Science University
School of Medicine
Report Assimilation Group Liaison
Sharon-Lise Normand, PHD
Harvard Medical School
Methodology Committee Chair
55. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
20
-
Develop Translation
Table/Tool (from research
question to design and
analysis)
Identify Standards for the use of data, design, and statistical analyses to
conduct patient centered outcomes research through:
Review current
methodological “state of
the art” statements issued
by expert bodies to guide
PCORI research
Research Methods Mission/Scope of Work
Review existing data
systems designed to
permit exploration of
causal questions from data
gathered in the course of
clinical practice. Identify
PCORI role in this arena.
56. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
21
Research Methods Progress to Date
Established initial
specifications for
dimensions to be used
in translation
instrument, with
options for
implementation
Developing
prototype for
standards
documents that
combines expert
statements,
published examples
and PCORI MC input
Interviewing leading
researchers of
electronic data, from
which research and
methods
recommendations
will be developed
57. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
22
Research Methods Progress to Date (Detailed)
Framework for
Methods Standards /
Recommendations
1. Method
2. Key sources
3. Major recommendations
4. PCORI MC commentary
5. Published examples
6. Tools for researchers
Translation Table
Dimensions
Intrinsic Factors
• Internal validity (aka bias)
• External validity (aka
generalizability, transportability)
• Precision
• Heterogeneity in risk or benefit
(aka “personalized” evidence)
• Ethical dimensions
Extrinsic Factors
• Timeliness (Rapidly changing
technology, policy urgency)
• Logistical burden (e.g. study
size, complexity, cost)
• Constraints (Data availability,
randomization possible?)
Question: condition, population, treatment & comparator, outcomes, setting
58. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
23
Finalize translation table dimensions and
determine categories of development
Finalize “standards” document format and
determine categories of development
Finish and summarize electronic data
systems environmental scan
Research Methods Next Steps
(e.g. diagnostic tests, missing
data, systematic reviews, etc.)
(e.g. drug safety, therapeutic
efficacy, etc.)
Jan. 2012 Workshop
59. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
24
Research Methods Question
Can the Board provide feedback on
the preliminary formats developed
(i.e., translation table dimensions
and methods standards format)?
60. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
25
Report Assimilation Workgroup
Mark Helfand, MD
Oregon Health & Science University
School of Medicine
Workgroup Chair
Alfred Berg, MD, MPH
University of Washington
Workgroup Member
David Flum, MD, MPH
University of Washington
Workgroup Member
Howard Balshem, MS
Oregon Health & Science University
Interim Researcher
Sherine Gabriel, MD
Mayo Clinic
Workgroup Member
Sharon-Lise Normand, PHD
Harvard Medical School
Workgroup Member
61. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
26
• Establishment
• Overview
• Structure
• Timeline
• Mission
• Scope of Work
• Progress to Date
• Next Steps
• Questions
1. Methodology Committee
2. Methodology
Committee Workgroups
3. Wrap Up
• Next Steps
62. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
27
Solicitation Responses and Questions Received to Date
Methodology Committee Next Steps
Letters of Intent
Received**
Questions
Patient Centeredness WG --
Stakeholder Interviews
25 8*
Patient Centeredness WG -
Literature Review
26 4*
Research Prioritization WG -
White Papers
11 0
**as of 9/16 at 8:30 a.m.
*This number of questions
includes a document
containing 13 individual
sub-questions.
63. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
28
Administrative
Review
Content
Review
Programmatic
Review
Executive
Decision
1. Clear, transparent and reproducible review process based on best
practices (eg. NIH)
2. Aligned with PCORI Vision, Mission, Principles and Policies (eg CoI)
3. Timely (~Applicants notified of award two weeks after submission)
Will be Established prior to receipt of first response (September 30, 2011)
Solicitation Review Process and Principles
Methodology Committee Next Steps
64. PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
29
Methodology Committee Next Steps
Research
Methods
Aug „11 Sep „11 Oct „11 Nov „11 Dec „11
Patient-
Centeredness
Jan „12 Feb „12 Mar „12 Apr „12 May „12
Workshop
Final
Report
Workshop
Identify
Gaps/
Issues
Translation
Table/Tool
Workshop Final
Papers
Due
Final
Draft
Final
Report
Final
Report
Compile
First
Draft
Legend
Research
Prioritization
Report
Assimilation
Feb – Jul „11
Revise Report Outline & Edit Chapters
Final
Report
Final
Papers
Due
Electronic Data Systems Landscape Review
Identify & Implement Voting
Standards Process
Solicitations: White Papers/Identify Experts
Solicitations: Literature Review & Interviews
MC
Charter
MC
Work
Plan
Interim
Researchers
Staffed
PCOR
Definition
Solicitation
Commission White Papers
66. Presentation to PCORI Board of Governors
September 20, 2011
PATIENT-CENTERED OUTCOMES
RESEARCH INSTITUTE:
Program Development Committee
67. Program Development Committee
Committee Members
• Carolyn Clancy
• Francis Collins
• Arnold Epstein
• Christine Goertz
• Leah Hole-Curry
• Gail Hunt
• Harlan Krumholz
• Richard Kuntz
Methodology Committee
Representatives
• Sherine Gabriel
• Sharon-Lise Normand
68. Report Outline
PCORI Pilot Project Grant Program
National Priorities and Research Agenda
Landscape Review Program
Program Development Committee
69. Presentation to PCORI Board of Governors
September 20, 2011
Christine Goertz, DC, PhD
PCORI Pilot Projects
70. Report Outline:
• Purpose of PCORI Pilot Projects
• PCORI Funding Announcement - Key Highlights
• Areas of Interest
• Overview of the Four-Stage Review Process
• Application Review Criteria
• Grant Application & Instructions
• Webinar & Process to Handle Inquiries
• Timeline, Key Dates, and Activities
71. Purpose of PCORI Pilot Projects
The purpose of the PCORI Pilot Projects Grant Program is threefold:
1. National Priorities. Pilot projects will provide information to
PCORI that informs future iterations of national research priorities
for patient centered outcomes research.
2. Research Agenda. The program will support the collection of
preliminary data that can be used to advance the field of patient-
centered outcomes research, providing the platform for an
evolving PCORI research agenda.
3. Methodologies. The program will support identification of
research methodologies that advance patient-centered outcomes
research
72. PCORI Funding Announcement:
Key Highlights
Applicants must address at least one of the eight areas of interest.
Stakeholder involvement is required unless the application can sufficiently
explain why it is not feasible.
Expect to commit approximately $13 million in FY 2012 to support
approximately 40 projects.
Applicants can propose project periods of up to two years. Second year
funding is subject to noncompetitive review by PCORI staff.
Direct costs are limited to $250,000 per year with an additional 40% of
salary and fringe allowable as indirect costs.
Letters of intent are due on November 1 with applications due on
December 1.
NIH will conduct the merit review process with all other aspects of grant
awards and grants management handled by PCORI.
73. Areas of Interest: Development
Areas of Interest
Board
Members
Methodology
Committee
Stakeholder /
Public Input
Projects focused on developing,
testing, and/or evaluating
methods or approaches that:
Inform the evolving
National Priorities
Bring together different
stakeholders
Translate research into
practice
Identify gaps in relation to
issues for disadvantaged
populations
Identify predictors of
patient outcomes
74. Areas of Interest
Developing, testing, refining, and/or evaluating new or existing methods (qualitative and quantitative) and
approaches that can inform the process of establishing and updating national priorities for the conduct of
patient-centered outcomes research (PCOR). This may include research prioritization approaches (such as
Value of Information (VOI), burden of illness, peer review/expert opinion/Delphi approaches) or methods for
incorporating the perspectives of patients or other stakeholders into the development of national priorities.
Developing, testing, and/or refining existing methods for bringing together patients, caregivers, clinicians
including non-traditional partners, and other stakeholders in all stages of a multi-stakeholder research
process, from the generation and prioritization of research questions to the conduct and analysis of a study to
dissemination of study results – including methods for training participants in participatory research and the
potential use of new technologies to facilitate engagement.
Developing, refining, testing, and/or evaluating patient-centered approaches, including decision-support
tools, for translating evidence-based care into health care practice in ways that account for individual patient
preferences for various outcomes. This may include developing or comparing conceptual models of
translation or dissemination of CER research findings from the patient perspective.
Developing, refining, testing, and/or evaluating methods to identify gaps in CE knowledge such as tools for
the ongoing collection and assessment of gaps as perceived by patients and providers. Of special interest are
gaps that are particularly relevant to vulnerable populations, including but not limited to, low-income
populations; minorities; children; elderly; women; people with disabilities, chronic, rare and/or multiple
medical conditions.
75. Areas of Interest
Identifying, testing, and/or evaluating patient-centered outcomes instruments. This may include predictive
tools (eg: instruments that measure or predict outcomes of interest to patients) or identifying standards for
measurement properties of patient-reported outcomes for use in comparative effectiveness research, across a
variety of interventions and patient populations.
Identifying, testing, and evaluating methods that can be used to assess the patient perspective when
researching behaviors, lifestyles, and choices within the patient’s control that may influence their outcomes.
Identifying, testing, refining and/or evaluating methods for studying the patient care team interaction in
situations where multiple options for wellness, prevention, diagnosis or treatment exist. Of special interest
are strategies that respect patient autonomy and promote informed decision-making, incorporating the best
health care knowledge into the application of care.
Advancing analytical methods for CER. Examples include but are not limited to the incorporation of mixed
methods research designs (qualitative/quantitative), identifying existing methodology to statistically
accommodate irregularly spaced multivariate longitudinal data, the use of instrumental variables; and
potential solutions for assessing treatment heterogeneity in observational and randomized CER studies.
76. Overview of the 4-Step Process
Preliminary
Check
Merit Review
Deliberation
Business
Determination that the application meets the minimum technical
requirements enumerated in the PFA and fits within programmatic
priorities.
PCORI Responsive/eligible
applications will be
forwarded for
review.
Remaining applications are assigned to 3 reviewers with
appropriate expertise who will critique independently and then
meet to discuss and designate a final score.
NIH A rank-ordered list
of applications and
summary sheets
The Pilot Projects Review Committee considers the merit review
scores and programmatic balance across several categories to
develop a recommended award slate for consideration by the BOG.
PCORI Funding decisions
are made.
A final review for suitability to manage an award, adherence to
human subjects requirements, receipt of IRB approval, budget
review, etc.
PCORI Negotiations,
where needed
Description Responsible Result
77. Preliminary Check
Technical
Requirements
• Receipt of Letter of
Intent
• Eligible applicant
• Stakeholder
requirements
• Page limit and
formatting
requirements
• Deadline met and
application properly
submitted
Programmatic
Requirements
• Does the application
fit within PCORI
program requirements
listed in the PFA?
Transfer to NIH
• Applications meeting
both technical and
programmatic
requirements will be
forwarded to NIH for
the Merit Review.
Conducted by PCORI staff
78. Merit Review
Prior to the Review
Meeting
• Each application is
assigned to 3 reviewers
• Reviewers include
scientists and other
stakeholders
• Stakeholders without
previous review
experience will be trained
• Reviewers assign an initial
priority score of 1 to 9
based on PCORI-provided
review criteria
• Provides basis for
discussion at in person
meeting
In-Person Review
• In-person meeting of
reviewers to discuss the
most promising
applications
• Review and discuss
applications based on
impact, stakeholder
involvement, innovation,
and significance of the
science
• Provide a final priority
score of 1 to 9
• Scientific Review Officer
compiles a summary
statement with reviewer
critiques for each
application
Summary & Rankings
• The review process
results in a ranked, scored
summary of applications
for PCORI consideration
Conducted by NIH
79. PCORI Deliberations
PCORI Staff
• Analyzes the applications
using priority score and
classification categories.
• Creates funding scenario
options based on
analytics.
• Supports the PCORI
Review Committee and
Board of Governors by
providing revised options,
as needed.
PCORI Review
Committee
• Meets to review materials
• Considers the balance of
priority-scored
applications across
classification categories,
requesting additional
analysis and options from
staff, as needed
• Prepares a recommended
slate of selected projects
for funding consideration
Board of Governors
• Meets to consider the
recommended slate
• Reviews the slate based
on priorities and balance
to ensure appropriate
distribution
• Requests additional
options, if needed
• Approves a final slate of
selected projects for
funding
Classification categories may include: Applicability of the 8 areas of interest, geographic
distribution, research methodology, and identification of target populations.
80. Recommended Funding
Slate Analysis
Following the Review
Committee meeting, analysts
will prepare the recommended
slate along with accompanying
analysis for consideration by
the Board of Governors.
81. Merit Review Criteria
Significance. Does the project address an important problem or a critical barrier to patient-
centered outcomes research? Does the project address one of the key questions outlined in
the PCOR definition described above? Is the project focused on one of the areas of interest
identified in this PFA? Will the results produce new knowledge that can advance PCOR
methods or infrastructure? Does the investigator demonstrate thorough knowledge of
previous and ongoing work related to their proposed topic?
Patient/Stakeholder Engagement. Will the research make a unique contribution to learning
about engagement of patients and non-traditional stakeholders in PCOR research efforts?
Does the research team demonstrate authentic, feasible, sustainable, novel partnerships with
patients, families and care givers, providers, and other appropriate non-traditional
stakeholders? Is there evidence that non-traditional stakeholders were involved in the
preparation of the research proposal?
Investigator(s). Is the research team well suited to the project? Is it multi-disciplinary? Is
there appropriate scientific expertise? Does at least one member of the study team have
experience in patient and other stakeholder engagement? Is there a high level of confidence
that the Principle Investigator and rest of the study team will be able to achieve the study
aims as described? Does the study team have complementary and integrated expertise; are
their leadership approach, governance and organizational structure appropriate for the
project?
82. Merit Review Criteria
(continued)
Innovation. Does the project either address a new method or approach or apply a proven
method or approach in a novel way to the field of PCOR? Is a refinement, improvement, or
new application of theoretical concepts, approaches or methodologies, instrumentation, or
interventions proposed?
Approach. Are the overall strategy, methodology, and analyses well-reasoned and appropriate
to accomplish the specific aims of the project? Are potential problems, alternative strategies,
and benchmarks for success presented? Will the strategy establish feasibility and will
particularly risky aspects be managed? Is the proposed budget and timeframe appropriate for
the research plan? Are there appropriate plans for dissemination among key PCOR
stakeholders in education, practice and policy?
Environment. Will the environment in which the work will be done contribute to the
probability of success? Are the institutional support, equipment and other physical resources
available to the investigators adequate for the project proposed? Will the project benefit from
unique features of the research environment, community involvement, patient populations,
or non-traditional stakeholder collaborative arrangements?
83. Grant Application & Instructions
• Application is based on the NIH PHS 398 form
with changes to ease responses and to meet the
needs of PCORI.
• Applicants will be bound by the Human Subjects
policies of NIH and will include appropriate
plans within the Research Strategy section.
• Applicants will provide information related to
classification categories to enable the Review
Committee and Board to consider this
information when developing a balanced slate
for funding.
Self-Reported
Classification Categories:
• Applicability of the “4
questions” to the research
• 8 areas of interest
• Identification of specific
populations including:
― Underserved or
disadvantaged
populations
― Specific ethic or cultural
populations
― Rural or urban
populations
― Disabled populations
84. Webinar & Inquiry Process
• Webinar for Applicants: October 12, 2011 at 2PM EST.
• Policy for responding to inquiries:
– A set of FAQs will be developed and issued along with the PFA with
frequent updates posted on the PCORI website. Questions and
answers will be framed in terms of general applicability.
– Inquiries should be directed to the PCORI website at pcori.org. PCORI
staff and appropriate consultants will receive, triage, route, and ensure
answers are provided and shared generally through the website.
85. Timeline, Key Dates, and Activities
2011
09 /11
PFA Posted
11/01/11
Letters of
Intent Due
12/1/11
Applications
Due
11-12/11
Identification of
Merit Reviewers
2012
12/11
Completeness/
Compliance/
Eligibility Check
2/12
Merit Review
3/12
Slate of Projects
to Board &
Selection Made
05/12/12
Award
Notification &
Funding
PCORI Applicant NIH/PCORI Applicant
PCORI NIH PCOR PCORI / Applicant
91. Environmental
scan of existing
priorities and
criteria
Candidate
priorities and
criteria
identified
Framework to
inter-relate
Priorities and
Criteria
Reviewed initial
stakeholder
input advising us
to not “reinvent
the wheel.”
Reviewed prior
CER frameworks
(e.g., IOM,
FCCCER,
National
Priorities
Partnership,
NQF)
Identified broad
priorities and
criteria that
were used often
in prior
frameworks and
fit PCOR.
Framework to be
used for refining
priorities, and
determining
Research
Agenda and
PFAs.
Initial
Stakeholder
feedback
Development of a National Priorities Framework
92. Previous priorities have varied in granularity
Granularity
IOM 2009
(e. g., Compare the effectiveness of upper endoscopy
utilization and frequency for patients with
gastroesophageal reflux disease on morbidity, quality of
life, and diagnosis of esophageal adenocarcinoma.)
National Priorities
Partnership
(e. g., Engage patients and
families in managing their health
and making decisions about their
care.)
National Prevention
Council
(e. g., Elimination of
health disparities)
FCCCER
(e.g., Expanding high-impact patient
registries)
National Quality
Forum
(e. g., Infrastructure –
Information Technology)
Least Most
National Quality
Strategy
(e. g., Promoting
effective communication
and coordination of care)
93. Ten candidate priorities
consistent with prior efforts
Source
Prevention
Acute
Care
Chronic
Disease
Care
Palliative
Care
Care
Coordination
Patient
Engagement
Safety
Appropriate
Use
HIT
to
Improve
Patient
Experience
Impact
of
New
Technology
IOM 2009: Priorities for
CER
√ √ √ √ √ √ √ √ √
Federal Coordinating
Committee for CER
√ √ √ √ √
AHRQ National Quality
Strategy
√ √ √ √
AHRQ Effective Health
Care Program
√ √ √ √ √ √
National Quality Forum √ √ √ √ √ √ √ √
National Prevention
Council
√ √
National Priorities
Partnership
√ √ √ √ √ √
94. Proposed criteria include
those in statute and
additional criteria
Used in Prior
Efforts
Criterion
Required in
statute
√ Impact on Health √
√ Improvability via Research √
√ Inclusiveness of Subpopulations √
√ Impact on Health System Performance √
√ Gaps in Knowledge √
√ Variation or Disparities in Delivery or Outcomes √
√ Potential to Inform Decision-Making at Point of Care √
√ Responsiveness to Expressed Needs √
Advances CER Methods
Fits the Definition
95. •Impact on Health of Individuals and Populations
•Probability of Improvability via Research
•Inclusiveness of Different Sub-populations
•Current Gaps in Knowledge / Variation in Care
•Impact on Health System Performance
•Current Health Disparities
•Potential to Influence Decision-Making at Point of Care
•Responsiveness to Expressed Needs
•Advances CER Methods
•Fits the Definition of PCOR
Framework to Inspire Drafting of PCOR-
Specific National Priorities
Health Information
to Improve Patient
Experience
Prevention &
Screening
Acute Care
Impact of New
Technology
PCORI National Priorities
(Illustrative Examples)
Prevention & Screening
Develop information that will guide
patients and providers to improve
outcomes in chronic conditions.
Develop information to help patients
coordinate their care across multiple
providers and care settings.
Develop evidence to help patients
improve the safety of their health
care.
Appropriate Use
PCORI Criteria
Proposed PCORI Criteria
Existing
Priority Areas
In
Statute
Chronic Disease
Care
Palliative Care &
Pain Management
Care Coordination
Patient
Engagement
Safety
98. PATIENTS PROFESSIONAL ORGANIZATIONS
Individuals with Disease
Families
Caregivers
Patient Advocacy Groups
General Public
Providers & Practitioners
Employers
Payers
Research Societies
Academia
Health Information Exchanges
Federal/State/Local
Government
Congress
Life Sciences Industry
Who are PCORI’s
stakeholders?
Key Stakeholder Groups
99. Proposed Stakeholder Engagement Timeline
Create
Engagement
Plan
and Identify
Stakeholders
Decide on
Content,
Methods
of Dialogue
Conduct Dialogue with
Stakeholders
Review,
incorporate
and Report
on
Feedback
September October November December
Week
1
Week
2
Week
3
Week
4
Week
5
Week
6
Week
7
Week
8
Week
9
Week
10
Week
11
Week
12
Week
13
Week
14
Week
15
Week
16
* *
* Board Meetings
*
102. Goals of Landscape Reviews
• Identify existing knowledge and gaps in existing knowledge related
to PCOR and CER
• Avoid funding patient-centered outcomes research that duplicates
ongoing or existing research
• Provide background information to spur innovation in research and
methodology, and contribute to the infrastructure for conducting
patient-centered outcomes research
• Create shared understanding about the state of the art of
dissemination and patient engagement strategies and contribute
to best practices
• Provide input into National Priorities and Research Agenda
103. Chronology of Landscape Review Development
Initial Phase:
Environmental Scan of
Comparative
Effectiveness Research
Discovery Phase:
Learning about
Lewin Group
Inventory of CER
Refining the Scope of
Landscape Reviews &
Methodology
Committee
Requirements
Coordination of
Landscape
Reviews across
PCORI: Landscape
Review Program
Landscape Review Program:
• Process to initiate and manage landscape reviews
• Templates to develop contract specifications and budget
requirements
• Resource library to share findings
104. Landscape Review Process Overview
Confirm questions
to be answered
Document known
information & gaps
Assess relevance /
usefulness of
information
Engage with NIH,
AHRQ, others to
leverage work of
interest to PCORI
Identify additional
information
needed
Prepare RFI as
needed to acquire
information
PCORI RESOURCE LIBRARY
105. Landscape Reviews/Summaries Completed or Underway
Report Status
“Existing and Ongoing NIH Work Related to Dissemination of Research: Overview
of NIH Briefing Book”
Completed 06/04/2011
“Existing and Ongoing Work Related to Patient Involvement in Peer Review:
Overview of NIH Briefing Book”
Completed 06/04/2011
“Overview of Lewin CER Inventory Project” Completed 07/07/2011
“Organizations that Conduct CER” Completed 08/09/2011
Review and Synthesis of Evidence for Eliciting the Patient’s Perspective in Patient-
Centered Outcome Research (Literature Review)
RFP issued 8/31/2011
Expert Stakeholder Interviews to Identify Evidence for Eliciting the Patient’s
Perspective in Patient-Centered Outcome Research (Interviews)
RFP issued 8/31/2011
Landscape review of existing methodological standards Under development by MC
Landscape review of patient engagement Under consideration by COEC